Hemoproteins for inhibition of nitric oxide-mediated hypotension and septic shock
US5480866A · kind A · utility
26Cited by
7References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 18, 1994 |
| Grant date | Jan 2, 1996 |
| Priority date | — |
| Expiry date | Jan 18, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is directed to a method for the prophylaxis or treatment of an animal for deleterious physiological effects such as systemic hypotension caused by nitric oxide production induced by a biological response modifier. Examples of such biological response modifiers include but are not limited to a cytokine and an endotoxin. The invention is also directed to a method for the treatment of septic shock. Hemoproteins such as hemoglobin, myoglobin, hemalbumin and methemalbumin, for example, are useful when administered to a hypotensive patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.